B41.7 Disseminated paracoccidioidomycosis

Name of the Condition

• Disseminated paracoccidioidomycosis

Summary

Disseminated paracoccidioidomycosis is a systemic fungal infection caused by Paracoccidioides brasiliensis or Paracoccidioides lutzii. It occurs when the infection spreads beyond the lungs to involve multiple organs, including the skin, mucous membranes, lymph nodes, and other tissues. This form of the disease is more severe and may present with widespread symptoms, reflecting the extent of fungal dissemination.

Causes

The infection originates from inhaling fungal spores present in soil or decaying organic matter. After entering the respiratory tract, the fungi can disseminate hematogenously to other parts of the body, leading to systemic involvement. The disease is not transmitted from person to person.

Risk Factors

• Residence or travel to endemic areas (e.g., parts of Brazil, Colombia, Venezuela).
• Occupational exposure to soil or agricultural activities.
• Immunocompromised states, such as HIV/AIDS, diabetes, or chronic steroid use.
• Male gender, as the disease is more prevalent in men.
• Smoking or chronic lung disease.

Symptoms

• Chronic cough, chest pain, or shortness of breath.
• Weight loss, fever, or night sweats.
• Widespread skin lesions (ulcers, nodules) or mucosal involvement (oral, nasal, or laryngeal ulcers).
• Lymph node enlargement, particularly in the neck or groin.
• Systemic symptoms indicating multi-organ involvement.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., chest X-rays or CT scans), and laboratory tests. Microscopic examination of tissue samples or body fluids (e.g., sputum, biopsy) may reveal the characteristic fungal yeast forms. Cultures or molecular tests (e.g., PCR) can confirm the presence of Paracoccidioides species. Serological tests may also be used to detect antibodies against the fungus.

Treatment Options

Treatment typically involves antifungal medications, such as itraconazole or amphotericin B, often administered for extended periods to ensure complete eradication of the fungus. The choice of drug and duration depends on the severity of the disease and the patient's overall health. Supportive care may be necessary to manage symptoms and complications.

Prognosis and Follow-Up

Prognosis varies based on the extent of organ involvement and the patient's immune status. Early diagnosis and appropriate treatment improve outcomes, but disseminated disease may have a more guarded prognosis, especially in immunocompromised individuals. Follow-up care includes monitoring for treatment response, potential relapse, and management of any residual organ damage.

Complications

• Severe respiratory failure due to extensive lung involvement.
• Dissemination to critical organs (e.g., central nervous system, adrenal glands).
• Chronic organ damage (e.g., fibrosis, scarring) from prolonged infection.
• Increased risk of secondary infections in immunocompromised patients.

Lifestyle & Prevention

• Avoiding exposure to soil or decaying organic matter in endemic areas, when possible.
• Using protective measures (e.g., masks) during activities that may aerosolize fungal spores.
• Maintaining overall health to support immune function.
• Seeking prompt medical evaluation for symptoms suggestive of fungal infection in endemic regions.

When to Seek Professional Help

Seek medical attention if you experience persistent respiratory symptoms, unexplained weight loss, fever, or skin/mucosal lesions, especially if you have lived in or traveled to endemic areas. Early intervention is critical for managing disseminated disease and preventing complications.

Tips for Medical Coders

• Use code B41.7 for documented cases of disseminated paracoccidioidomycosis.
• Ensure clinical documentation specifies the disseminated nature of the infection (e.g., involvement of multiple organs or systems).
• Verify that the diagnosis aligns with the clinical presentation and diagnostic findings to support accurate coding.